<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1271">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632043</url>
  </required_header>
  <id_info>
    <org_study_id>32635, 13-10-2020</org_study_id>
    <nct_id>NCT04632043</nct_id>
  </id_info>
  <brief_title>Early Versus Delayed Intubation of Patients With COVID-19</brief_title>
  <acronym>EUDOCO</acronym>
  <official_title>Effect of Early versUs Delayed intubatiOn on Clinical Outcomes of Patients With COVID-19 (EUDOCO): a Feasibility Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evangelismos Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evangelismos Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although management of acute hypoxemic respiratory failure associated with coronavirus&#xD;
      disease 2019 (COVID-19) often includes mechanical ventilation, the optimal timing of&#xD;
      initiation of invasive mechanical ventilation remains unknown.&#xD;
&#xD;
      We hypothesise that a randomized controlled trial comparing early intubation as opposed to&#xD;
      delayed intubation among patients with COVID-19 suffering from severe acute hypoxemic&#xD;
      respiratory failure is feasible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A common manifestation of COVID-19 is severe acute hypoxemic respiratory failure. Management&#xD;
      of acute hypoxemic respiratory failure associated with COVID-19 often includes mechanical&#xD;
      ventilation. The optimal timing of initiation of invasive mechanical ventilation remains&#xD;
      unknown.&#xD;
&#xD;
      On the one hand, early initiation of invasive mechanical ventilation (i.e. early endotracheal&#xD;
      intubation) has been advocated as a means to reduce subsequent possible aerosolization of the&#xD;
      virus, as would happen by alternate means of oxygenation/ventilation allowing air leaks.&#xD;
      Also, early intubation may prevent the induction of self-inflicted lung injury in patients&#xD;
      who breath spontaneously and have high respiratory drive and, therefore, large transpulmonary&#xD;
      pressure swings. On the other hand, delaying intubation, by trying alternate means of&#xD;
      oxygenation/ventilation, may mean that some of the patients may not be intubated at all and&#xD;
      therefore will be protected from the adverse events of invasive mechanical ventilation (such&#xD;
      as ventilator-induced lung injury, ventilator-associated pneumonia and ventilator-induced&#xD;
      diaphragmatic dysfunction). The latter strategy may also address the unavailability of enough&#xD;
      ventilators to meet the increased demand of treating patients with COVID-19.&#xD;
&#xD;
      Given that no randomized controlled trials are currently available to guide clinical practice&#xD;
      regarding optimal timing of intubation, we propose a single-center randomized controlled&#xD;
      feasibility trial to compare early intubation versus delayed intubation among patients with&#xD;
      COVID-19 suffering from severe acute hypoxemic respiratory failure. The aim is that we gain&#xD;
      experience and produce pilot data, which could inform the design of a subsequent large&#xD;
      multi-center clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from onset of severe acute hypoxemic respiratory failure to intubation</measure>
    <time_frame>28 days</time_frame>
    <description>Difference in time from onset of severe acute hypoxemic respiratory failure to intubation between the two groups will be the primary (feasibility) outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Organ failure-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days without the need for invasive mechanical ventilation, vasopressors and continuous renal replacement therapy with days after death not to be considered as organ failure-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for continuous renal replacement therapy</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Intensive care unit-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause ICU-mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe post-intubation adverse events</measure>
    <time_frame>Within 30 minutes from intubation</time_frame>
    <description>Cardiac arrest and severe arterial desaturation (defined as SpO2 &lt;80% for &gt;5 minutes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COVID-19</condition>
  <condition>Acute Hypoxemic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Early intubation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for more than mask venturi 50% to maintain a SpO2 &gt;92%) for at least 48 hours will undergo intubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed intubation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for more than mask venturi 50% to maintain a SpO2 &gt;92%) for at least 48 hours will continue to receive non-rebreather mask, high-flow nasal oxygen or non-invasive mechanical ventilation in an attempt to avoid intubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endotracheal intubation</intervention_name>
    <description>Endotracheal intubation</description>
    <arm_group_label>Delayed intubation</arm_group_label>
    <arm_group_label>Early intubation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult patients with confirmed COVID-19 and severe acute hypoxemic respiratory failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Postoperative acute respiratory failure (within one week from surgery)&#xD;
&#xD;
          -  After cardiac arrest&#xD;
&#xD;
          -  Chronic hypoxemic respiratory failure&#xD;
&#xD;
          -  Hypercapnic respiratory failure&#xD;
&#xD;
          -  No full code&#xD;
&#xD;
          -  Lack of equipoise of the clinical team&#xD;
&#xD;
          -  Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilias Siempos, MD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evangelismos Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilias Siempos, MD, DSc</last_name>
    <phone>+306948279049</phone>
    <email>isiempos@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Evangelismos Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Ilias Siempos, MD, DSc</last_name>
      <phone>+306948279049</phone>
      <email>isiempos@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <results_reference>
    <citation>Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA. 2020 Jun 9;323(22):2329-2330. doi: 10.1001/jama.2020.6825.</citation>
    <PMID>32329799</PMID>
  </results_reference>
  <results_reference>
    <citation>Fan E, Beitler JR, Brochard L, Calfee CS, Ferguson ND, Slutsky AS, Brodie D. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respir Med. 2020 Aug;8(8):816-821. doi: 10.1016/S2213-2600(20)30304-0. Epub 2020 Jul 6. Review.</citation>
    <PMID>32645311</PMID>
  </results_reference>
  <results_reference>
    <citation>Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR Jr, Nahid M, Ringel JB, Hoffman KL, Alshak MN, Li HA, Wehmeyer GT, Rajan M, Reshetnyak E, Hupert N, Horn EM, Martinez FJ, Gulick RM, Safford MM. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020 Jun 11;382(24):2372-2374. doi: 10.1056/NEJMc2010419. Epub 2020 Apr 17.</citation>
    <PMID>32302078</PMID>
  </results_reference>
  <results_reference>
    <citation>Bauer PR, Gajic O, Nanchal R, Kashyap R, Martin-Loeches I, Sakr Y, Jakob SM, Fran√ßois B, Wittebole X, Wunderink RG, Vincent JL; ICON Investigators (Supplemental Appendix 1). Association between timing of intubation and outcome in critically ill patients: A secondary analysis of the ICON audit. J Crit Care. 2017 Dec;42:1-5. doi: 10.1016/j.jcrc.2017.06.010. Epub 2017 Jun 16.</citation>
    <PMID>28641231</PMID>
  </results_reference>
  <results_reference>
    <citation>Kang BJ, Koh Y, Lim CM, Huh JW, Baek S, Han M, Seo HS, Suh HJ, Seo GJ, Kim EY, Hong SB. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intensive Care Med. 2015 Apr;41(4):623-32. doi: 10.1007/s00134-015-3693-5. Epub 2015 Feb 18.</citation>
    <PMID>25691263</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Evangelismos Hospital</investigator_affiliation>
    <investigator_full_name>Ilias Siempos</investigator_full_name>
    <investigator_title>Pulmonologist, Intensivist</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Within 3 months from publication</ipd_time_frame>
    <ipd_access_criteria>To anyone who is interested in writing a meta-analysis or review.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

